<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Handling of Active Substance Master Files and Certificates of Suitability from 1 January 2021
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">The MHRA will continue to accept Active Substance Master Files (ASMFs) and Certificates of Suitability (CEPs) from 1 January 2021.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>



  <section class="app-c-header-notice" aria-label="notice" role="region">
    <div class="app-c-header-notice__header">
      <h2 class="app-c-header-notice__title">New rules for January 2021</h2>
    </div>

    <div class="app-c-header-notice__content">
          <p class="app-c-header-notice__text govuk-body">The UK has left the EU, and the transition period after Brexit comes to an end this year.</p>
          <p class="app-c-header-notice__text govuk-body">This page tells you what you'll need to do from 1 January 2021. It will be updated if anything changes.</p>
        <div class="app-c-header-notice__links">
            <p class="govuk-body app-c-header-notice__link-intro">
              For current information, read: 
              <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk" data-track-label="Apply for a licence to market a medicine in the UK" class="app-c-header-notice__link" href="/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk">Apply for a licence to market a medicine in the UK</a>
            </p>
        </div>

        <p class="app-c-header-notice__text govuk-body">You can also read about <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/transition" data-track-label="the transition period" class="govuk-link" href="/transition">the transition period</a>.</p>
    </div>
  </section>


<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#active-substance-master-file-asmf" data-track-options="{"dimension29":"Active Substance Master File (ASMF)"}" href="#active-substance-master-file-asmf">Active Substance Master File (ASMF)</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#submissions-portal" data-track-options="{"dimension29":"Submissions Portal"}" href="#submissions-portal">Submissions Portal</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#certificates-of-suitability-ceps" data-track-options="{"dimension29":"Certificates of Suitability (CEPs)"}" href="#certificates-of-suitability-ceps">Certificates of Suitability (CEPs)</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<p>From 1 January 2021, the MHRA will continue to accept an Active Substance Master File and/or a Certificate of Suitability in both new national initial Marketing Authorisation Applications (<abbr title="Marketing Authorisation Applications">MAA</abbr>) and in Marketing Authorisation Variation (<abbr title="Marketing Authorisation Variation">MAV</abbr>) applications.</p>

<h2 id="active-substance-master-file-asmf">Active Substance Master File (<abbr title="Active Substance Master File">ASMF</abbr>)</h2>

<p>An <abbr title="Active Substance Master File">ASMF</abbr> should be prepared in accordance with the Committee for Medicinal Products for Human Use (CHMP) guideline on active substance master file procedure (<a rel="external" href="https://www.ema.europa.eu/documents/report/final-guideline-active-substance-master-file-procedure-revision-4_en.pdf" class="govuk-link">CHMP/QWP/227/02 Rev 4</a>).</p>

<p>Templates (letter of access; submission letter and administrative details form) included in the annexes to that guideline should continue to be used.</p>

<p>You should submit the Applicant’s Part (<abbr title="Applicant’s Part">AP</abbr>) of the <abbr title="Active Substance Master File">ASMF</abbr> as part of the <abbr title="Marketing Authorisation">MA</abbr> dossier, together with a letter of access issued by the <abbr title="Active Substance Master File">ASMF</abbr> holder.</p>

<p>When an <abbr title="Active Substance Master File">ASMF</abbr> procedure is to be used which relates to an <abbr title="Active Substance Master File">ASMF</abbr> that has not previously been submitted to the MHRA, the <abbr title="Active Substance Master File">ASMF</abbr> holder should submit a copy of the <abbr title="Applicant’s Part">AP</abbr> and Restricted Part (<abbr title="Restricted Part">RP</abbr>) to the MHRA. This should be accompanied by:</p>

<ul>
  <li>a completed submission letter and administrative details form</li>
  <li>any relevant letter of access</li>
  <li>the Quality Overall Summary for the <abbr title="Applicant’s Part">AP</abbr> and for the <abbr title="Restricted Part">RP</abbr>
</li>
  <li>a curriculum vitae for the Expert</li>
</ul>

<p>The complete <abbr title="Active Substance Master File">ASMF</abbr> only needs to be submitted once to register the <abbr title="Active Substance Master File">ASMF</abbr> with the MHRA. The relevant documentation should be timed to arrive at approximately the same time as the <abbr title="Marketing Authorisation Applications">MAA</abbr> or <abbr title="Marketing Authorisation Variation">MAV</abbr>, so not more than one month before and not after the intended <abbr title="Marketing Authorisation Applications">MAA</abbr>/<abbr title="Marketing Authorisation Variation">MAV</abbr> submission date.</p>

<p>Changes to an <abbr title="Active Substance Master File">ASMF</abbr> should be handled in accordance with the CHMP guideline (<a rel="external" href="https://www.ema.europa.eu/documents/report/final-guideline-active-substance-master-file-procedure-revision-4_en.pdf" class="govuk-link">CHMP/QWP/227/02 Rev 4</a>). The <abbr title="Active Substance Master File">ASMF</abbr> holder needs to fulfil their responsibilities with respect to notifying each Applicant/<abbr title="Marketing Authorisation">MA</abbr> holder and the MHRA, that changes are being proposed to the <abbr title="Active Substance Master File">ASMF</abbr>.</p>

<p>Submission of a new <abbr title="Active Substance Master File">ASMF</abbr> and any update to an <abbr title="Active Substance Master File">ASMF</abbr> should be made by the <abbr title="Active Substance Master File">ASMF</abbr> holder using the MHRA</p>

<h2 id="submissions-portal">Submissions Portal</h2>

<p>The UK will no longer participate in <abbr title="Active Substance Master File">ASMF</abbr> worksharing procedures with EU Member States. Any reference in the above guideline to the <abbr title="Communication and Tracking System">CTS</abbr> <abbr title="Active Substance Master File">ASMF</abbr> assessment repository or to EU/<abbr title="Active Substance Master File">ASMF</abbr>/XXXXX reference numbers will not be applicable to UK national applications from 1 January 2021.</p>

<p>Where an assessment of a new <abbr title="Active Substance Master File">ASMF</abbr> or an update to an <abbr title="Active Substance Master File">ASMF</abbr> has been conducted by an EU Member State before 1 January 2021, such an assessment may be taken into consideration in subsequent <abbr title="Marketing Authorisation Applications">MAA</abbr> or <abbr title="Marketing Authorisation Variation">MAV</abbr> applications that are under assessment after 1 January 2021.</p>

<h2 id="certificates-of-suitability-ceps">Certificates of Suitability (<abbr title="Certificates of Suitability">CEPs</abbr>)</h2>

<p><abbr title="Certificates of Suitability">CEPs</abbr> are not affected by the UK leaving the EU as they are issued by the <a rel="external" href="https://www.edqm.eu/" class="govuk-link">European Directorate for the Quality of Medicines and Healthcare (<abbr title="European Directorate for the Quality of Medicines and Healthcare">EDQM</abbr>)</a>. This is a Directorate of the Council of Europe and a body that is independent of the EU. On leaving the EU, the UK will remain a member of the Council of Europe and a signatory to the Convention on the Elaboration of a European Pharmacopoeia.</p>

<p>There will be no change to the procedures relating to the use of a CEP to support an <abbr title="Marketing Authorisation Applications">MAA</abbr> or <abbr title="Marketing Authorisation Variation">MAV</abbr>.</p>

<h3 id="action-for-marketing-authorisation-applicants">Action for Marketing authorisation applicants</h3>

<ul>
  <li>You should include appropriate information in the <abbr title="Marketing Authorisation Applications">MAA</abbr> or <abbr title="Marketing Authorisation Variation">MAV</abbr> application form.</li>
  <li>You should include a copy of the current version of the relevant CEP in Modules 1 and 3.</li>
</ul>

<p>The second of these actions relates to applications where there is:</p>

<ul>
  <li>a CEP for a chemical substance that is an active substance or excipient;</li>
  <li>a CEP for a herbal drug or herbal drug preparation</li>
  <li>a CEP for materials of animal or human origin that have been subject to an evaluation of the risk related to transmissible spongiform encephalopathies (TSE).</li>
</ul>

<p>This guidance will apply from 1 January 2021 in line with the <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made" class="govuk-link">Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019</a>. It is our intention to update these Regulations to reflect the change of implementation dates following the Transition Period.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">
    <div class="gem-c-contextual-sidebar__brexit-cta govuk-!-margin-bottom-6" data-module="track-click">
  <h2 class="gem-c-contextual-sidebar__brexit-heading">Transition period</h2>
  <a href="/transition" class="govuk-link" data-track-category="relatedLinkClicked" data-track-action="1.0 Transition" data-track-label="/transition" data-track-options="{"dimension29":"Find out what it means for you"}">Find out what it means for you</a>
</div>



    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-b3f7c0a6" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-b3f7c0a6" data-module="gem-toggle">

    <h3 id="related-nav-collections-b3f7c0a6" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="1.1 Collection" data-track-label="/government/collections/mhra-post-transition-period-information" data-track-options="{"dimension28":"1","dimension29":"MHRA post-transition period information"}" href="/government/collections/mhra-post-transition-period-information">MHRA post-transition period information</a></li>

  </ul>
</nav>

  </div>



</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-f6cd2c51" data-module="gem-toggle">

    <h2 id="related-nav-topics-f6cd2c51" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"1","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>